The EpiSwitch CST was developed by Oxford BioDynamics, a leader in the design of genomic tests that help people understand their disease risks and likely response to prescribed drugs.
Research and development of EpiSwitch, a proprietary, epigenetic, biomarker-discovery platform, first began at Oxford University, England in 2005. Once proof of concept was established in June 2007, a new company, Oxford BioDynamics, was spun out from the University with the aim of translating fundamental scientific advances into a commercialized platform technology that could leverage newly discovered epigenetic biomarkers to develop tests that predict an individual’s risk for a range of chronic diseases and cancer.
EpiSwitch research and medical analysis services focus on the discovery, evaluation, validation, and monitoring of changes in the 3-dimensional organization of the human genome (3D genomics) as a novel class of epigenetic biomarkers. Oxford BioDynamics has applied EpiSwitch in medical testing kits, prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. Monitoring 3D genomic changes by EpiSwitch can provide a compelling, stable readout of cellular changes, long before they manifest as a clinical sign or symptom.
The EpiSwitch platform was recognized by Frost & Sullivan as the Best European Biomarker Discovery Technology in 2015 and the company was a recipient of the 2019 Queen’s Awards for Enterprise in Innovation. EpiSwitch is poised to play a critical role in identifying individual disease risk profiles to optimize the diagnosis and management of a range of conditions and diseases to help advance personalized healthcare.